XML 37 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 25, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Entity Transition Report false    
Entity File Number 001-39990    
Entity Registrant Name Elicio Therapeutics, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 11-3430072    
Entity Address, Address Line One 451 D Street, 5th Floor    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02210    
City Area Code 857    
Local Phone Number 209-0050    
Title of 12(b) Security Common Stock, par value $0.01    
Trading Symbol ELTX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 33.2
Entity Common Stock, Shares Outstanding   15,953,524  
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement to be filed for the registrant’s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001601485    
Amendment Flag false